Alex G Hamilton
Overview
Explore the profile of Alex G Hamilton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Safford H, Shuler C, Geisler H, Thatte A, Swingle K, Han E, et al.
Nano Lett
. 2025 Mar;
PMID: 40084657
It is well established that the physicochemical properties of lipid nanoparticles (LNPs) can govern their interactions with various biological barriers. One property hypothesized to influence nanoparticle-cell interactions is elasticity. Here,...
2.
Swingle K, Hamilton A, Safford H, Geisler H, Thatte A, Palanki R, et al.
Nature
. 2025 Feb;
638(8051):E33.
PMID: 39900626
No abstract available.
3.
Han E, Tang S, Kim D, Murray A, Swingle K, Hamilton A, et al.
Nano Lett
. 2024 Dec;
25(2):800-810.
PMID: 39688915
Systemic delivery of large nucleic acids, such as mRNA, to the brain remains challenging in part due to the blood-brain barrier (BBB) and the tendency of delivery vehicles to accumulate...
4.
Swingle K, Hamilton A, Safford H, Geisler H, Thatte A, Palanki R, et al.
Nature
. 2024 Dec;
637(8045):412-421.
PMID: 39663452
Pre-eclampsia is a placental disorder that affects 3-5% of all pregnancies and is a leading cause of maternal and fetal morbidity worldwide. With no drug available to slow disease progression,...
5.
Mukalel A, Hamilton A, Billingsley M, Li J, Thatte A, Han X, et al.
Adv Funct Mater
. 2024 Dec;
34(27).
PMID: 39628840
Chimeric antigen receptor (CAR) monocyte and macrophage therapies are promising solid tumor immunotherapies that can overcome the challenges facing conventional CAR T cell therapy. mRNA lipid nanoparticles (mRNA-LNPs) offer a...
6.
Gong N, Zhong W, Alameh M, Han X, Xue L, El-Mayta R, et al.
Nat Mater
. 2024 Sep;
23(12):1736-1747.
PMID: 39223270
Nanoparticles are promising for drug delivery applications, with several clinically approved products. However, attaining high nanoparticle accumulation in solid tumours remains challenging. Here we show that tumour cell-derived small extracellular...
7.
Swingle K, Hamilton A, Mitchell M
Placenta
. 2024 Aug;
PMID: 39181830
Clinically approved therapeutics for obstetric conditions are extremely limited, with over 80% of drugs lacking appropriate labeling information for pregnant individuals. The pathology for many of these obstetric conditions can...
8.
Palanki R, Riley J, Bose S, Luks V, Dave A, Kus N, et al.
Proc Natl Acad Sci U S A
. 2024 Jul;
121(32):e2400783121.
PMID: 39078677
Monogenic blood diseases are among the most common genetic disorders worldwide. These diseases result in significant pediatric and adult morbidity, and some can result in death prior to birth. Novel...
9.
Hamilton A, Swingle K, Thatte A, Mukalel A, Safford H, Billingsley M, et al.
ACS Nano
. 2024 Jun;
18(25):16151-16165.
PMID: 38861479
Immune modulation through the intracellular delivery of nucleoside-modified mRNA to immune cells is an attractive approach for immunoengineering, with applications in infectious disease, cancer immunotherapy, and beyond. Lipid nanoparticles (LNPs)...
10.
Geisler H, Ghalsasi A, Safford H, Swingle K, Thatte A, Mukalel A, et al.
J Control Release
. 2024 May;
371:455-469.
PMID: 38789090
The full potential of ionizable lipid nanoparticles (LNPs) as an in vivo nucleic acid delivery platform has not yet been realized given that LNPs primarily accumulate in the liver following...